Scholar Rock Holding Corp

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The firm offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Scholar Rock advances myostatin programs, eyes regulatory milestones in 2024

Scholar Rock's Q3 performance reflects progress in myostatin programs and expansion into cardiometabolic disorders, supported by strong financials and partnerships.
The company's focus on myostatin biology, promising results of apitegromab and SRK-439, and engagement with regulatory authorities position them for future success.
While facing challenges in statistical assumptions, patient variability, and therapy safety, Scholar Rock's deep understanding of myostatin presents opportunities for growth and innovation.

Scholar Rock excels in Q3 with SMA breakthrough and strong financial backing

Scholar Rock's Q3 performance showcases promising advancements in SMA treatment and strategic initiatives to drive future growth and commercial success.
The company's strong financial position, diverse pipeline, and focus on patient-centric care position them well for potential market leadership.
While facing challenges in regulatory approval and market competition, Scholar Rock's proactive approach and innovative drug candidates present significant opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Scholar Rock Holding Corporation (SRRK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 43.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Scholar Rock Holding Corporation (SRRK)

Scholar Rock Holding Corp (NASDAQ: SRRK) plans to reduce its overall headcount by 25%, and its Chief Medical Officer Yung Chyung will step down by the end of June.  "Parting with employees who have dedicated their talent and expertise to evolving a scientific platform into.

Scholar Rock Shares Jumps On Updating Strategic Priorities

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided a business update and reported financial results for the first quarter ended March 31, 2022. Business Strategy & Update Prioritize R&D Activities to Support Progression and Completion of the Apitegromab Phase 3 SAPPHIRE Trial in Spinal Muscular Atrophy. Schol

Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it is delivering a podium presentation at the 14th European Paediatric Neurology Society (EPNS) Congress, taking place in Glasgow, UK from April 28 - May 2, 2022. Details of the podium presentation are as follows: Title: Apitegromab in Spinal Muscular Atrophy (SMA): An

Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress

Scholar Rock Holding Corporation (SRRK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Scholar Rock Holding Corporation (SRRK) Stock Jumps 9.2%: Will It Continue to Soar?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today announced that it is presenting encore data in an e-poster at the American Academy of Neurology (AAN) 2022 Annual Meeting.

Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announces a poster presentation at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, March 13 - 16.

Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of 6.73% and 4.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the full year ended December 31, 2021, and highlighted recent progress and upcoming milestones for its pipeline programs. “We are excited by the momentum and engagement around our ongoing Phase 3 SAPPHIRE trial of apitegromab in spinal muscular atrophy,

Scholar Rock Reports Full Year 2021 Financial Results and Highlights Business Progress

Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q4 Earnings Expected to Decline

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in an Orphan Neuro and Neuromuscular panel discussion at Cowen's 42nd Annual Health Care Conference on Monday, March 7, 2022 at 9:10 a.m. ET. A live webcast of the presentation may be accessed by visiting the Investors & Media section of

Scholar Rock to Present at Cowen's 42nd Annual Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today announced a presentation at the 2nd Annual TGFβ for Immuno-Oncology Drug Development Summit (January 25-27, 2022).

Scholar Rock to Present Biomarker Strategy for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for its pipeline programs in 2022. “2021 was another transformative year for Scholar Rock, with positive data from both of our clinical programs, including from the TOPAZ Phase 2 trial for apitegromab, which is bei

Scholar Rock Provides Corporate Update and Highlights Priorities for 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 7:30 a.m. ET. A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.s

Scholar Rock to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the study design for SAPPHIRE, a Phase 3 trial of apitegromab, a selective inhibitor of the activation of latent myostatin. This pivotal trial will evaluate the efficacy and safety of apitegromab in patients with non-ambulatory Type 2 and Type 3 spinal muscular atrophy (SMA

Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today presented initial clinical data from Part A of its DRAGON Phase 1 proof-of-concept trial at the SITC Annual Meeting.

Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -20.00% and 24.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the third quarter ended September 30, 2021, and highlighted recent progress and upcoming milestones for its pipeline programs. “The DRAGON trial addresses two key questions; first, can the selectivity of SRK-181 for TGFβ1 increase the therapeutic window

Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences: Credit Suisse 30th Annual Virtual Healthcare Conference on Tuesday, November 9th, 2021 at 8:50 a.m. ET. Cowen 5th Annual IO Next Virtual Summit on Monday, November 15th, 2021 at 8:15 a.m. ET. 1

Scholar Rock to Present at Upcoming Healthcare Conferences

Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q3 Earnings Expected to Decline

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announces an e-poster presentation of clinical results from the TOPAZ Phase 2 trial at the 25th World Congress of Neurology (WCN).

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced a late breaker poster presentation as part of the 50th Child Neurology Society (CNS) Annual Meeting, occurring 9/29 - 10/2.

Scholar Rock Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the Child Neurology Society Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced that the USPTO issued U.S. Patent No. 11,130,803, with projected expiry of May 2040, providing product protection for SRK-181.

Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock is announcing two poster presentations as part of the World Muscle Society (WMS) Virtual Congress taking place September 20-24, 2021.

Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29th, 2021 at 11:20 a.m. ET. A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://i

News for Scholar Rock Holding Corp Stock (SRRK)